Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 300 versus MD 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 300 versus MD 76.
IOPAMIDOL-300 vs MD-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble iodinated contrast agent that attenuates X-rays, thereby enhancing radiographic visualization of vascular structures and organs. It does not bind to receptors and has no significant pharmacological activity.
MD-76 is a contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast between vascular structures and surrounding tissues. It distributes in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Intravenous or intra-arterial administration; dose varies by procedure (e.g., 1-2 mL/kg for CT, up to 50-100 mL for angiography) up to a maximum of 200 mL per procedure.
IV: 50-100 mL per dose, administered as a bolus or infusion, not to exceed 3 mL/kg total dose.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (creatinine clearance >90 mL/min). In moderate renal impairment it extends to 3-5 hours; in severe renal impairment (CrCl <30 mL/min) it can exceed 30 hours, prolonging diagnostic window.
Terminal half-life: 1.5–2 hours; prolonged in renal impairment (up to 20 hours in anuria); clinical context: allows rapid elimination, suitable for diagnostic imaging
Primarily renal excretion of intact drug via glomerular filtration; >90% excreted unchanged in urine within 24 hours. Less than 1% fecal or biliary elimination.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent